Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Drug Discovery Spotlight: Female Libido Drug FDA Recommended; Oncology Meeting Highlights

By Drug Discovery Trends Editor | June 5, 2015

This week witnessed an FDA recommendation of a twice-rejected female libido drug. And more than 30,000 oncology professionals from around the world gathered at ASCO 2015 to discuss groundbreaking research and ongoing controversies in the field.

(AP Photo/Allen G. Breed)FDA Panel Recommends Female Libido Drug

In a move heralded as a ‘major victory for a drug that’s been twice rejected by the FDA since 2010, an FDA advisory panel voted 18 to 6 to recommend the agency approve flibanserin — nicknamed ‘women’s Viagra — as the first prescription treatment to boost libido in women.

​ASCO 2015 Highlights

The research at the American Society of Clinical Oncology (ASCO) Annual Meeting produced hundreds of headlines this week. Here are a few of the top news, from an immunotherapy drug that disappointed investors to a hefty-priced combined drug regimen that although beneficial, increased side effects.

Onxeo Announces New Data for Two Orphan Oncology Drugs

Drug Discovery & Development spoke with European pharma company Onxeo’s CSO, Graham Dixon, on new data for two of its lead products, Belinostat and Validive, and on where the orphan oncology market is headed.

Strongest Statin-Diabetes Link Yet? Not So Fast, Say Some Experts

A recent study in the Journal of General Internal Medicine found that out of 26,000 healthy people, those taking statins to control cholesterol were a striking 87 percent more likely to become diabetic. However, some experts are pointing out a number of flaws in the study.

High Blood Pressure Drug May Also Have Anti-Parkinson’s Effect

A common, FDA-approved high blood pressure drug may also combat the immune response occurring in —and accelerating — Parkinson’s disease, reports a Georgetown University and University of Colorado team in Science Signaling.


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50